The microbiota represents a formidable instructor of the immune system, affecting systemic immune responses. Chronic inflammation, a driver of many diseases and a key determinant of the aging process, has been linked with different microbiota components, pathways, and configurations. However, despite many exploratory studies targeting the microbiota to elicit protective immune responses, it is unclear how we can induce stable beneficial changes in the gut microbiota. In addition, the mechanisms underlying the host-microbiota interactions determining chronic inflammation deserve further attention, and the microbiota components driving the effects need to be better characterized.
This research topic aims to highlight translational research and clinical trials evaluating the immunological effects of interventions on the gut microbiota, such as dietary or pharmacological interventions, postbiotics, phage therapy, or fecal microbiota transplant, in conditions associated with chronic inflammation or immunosenescence.
We welcome original research, review, mini-review, and perspective articles on the following areas:
-Interventions on the gut microbiota in diseases characterized by chronic inflammation, including, but not limited to, infectious diseases, gastrointestinal diseases, autoimmune diseases, and cancer.
-Potential of the microbiome to boost immunotherapy responses in cancer.
-Mechanistic studies explaining changes in microbiota-host interactions following interventions on the gut microbiota.
-Translational research identifies mechanisms by which the microbiota trigger or sustain chronic inflammation.
Topic Editor Giulia Marchetti was part of advisory boards for Gilead, VIIV, and Jannsen. Topic Editor Sergio Serrano-Villar received financial support from MSD and financial support and personal fees from Gilead. The other Topic Editors declare no competing interests.
The microbiota represents a formidable instructor of the immune system, affecting systemic immune responses. Chronic inflammation, a driver of many diseases and a key determinant of the aging process, has been linked with different microbiota components, pathways, and configurations. However, despite many exploratory studies targeting the microbiota to elicit protective immune responses, it is unclear how we can induce stable beneficial changes in the gut microbiota. In addition, the mechanisms underlying the host-microbiota interactions determining chronic inflammation deserve further attention, and the microbiota components driving the effects need to be better characterized.
This research topic aims to highlight translational research and clinical trials evaluating the immunological effects of interventions on the gut microbiota, such as dietary or pharmacological interventions, postbiotics, phage therapy, or fecal microbiota transplant, in conditions associated with chronic inflammation or immunosenescence.
We welcome original research, review, mini-review, and perspective articles on the following areas:
-Interventions on the gut microbiota in diseases characterized by chronic inflammation, including, but not limited to, infectious diseases, gastrointestinal diseases, autoimmune diseases, and cancer.
-Potential of the microbiome to boost immunotherapy responses in cancer.
-Mechanistic studies explaining changes in microbiota-host interactions following interventions on the gut microbiota.
-Translational research identifies mechanisms by which the microbiota trigger or sustain chronic inflammation.
Topic Editor Giulia Marchetti was part of advisory boards for Gilead, VIIV, and Jannsen. Topic Editor Sergio Serrano-Villar received financial support from MSD and financial support and personal fees from Gilead. The other Topic Editors declare no competing interests.